Iterum Therapeutics Files 8-K on Security Holder Vote
Ticker: ITRM · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $1,800,000, $2,600,000 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Iterum Therapeutics plc filed an 8-K for a shareholder vote on 9/10/25.
AI Summary
Iterum Therapeutics plc filed an 8-K on September 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the nature of the vote or any outcomes, but it serves as a formal notification to the SEC.
Why It Matters
This filing indicates that Iterum Therapeutics plc is engaging in corporate governance activities requiring shareholder approval, which could impact the company's strategic direction or operational decisions.
Risk Assessment
Risk Level: low — The filing is a procedural notification of a shareholder vote without disclosing specific outcomes or controversial proposals, thus posing minimal immediate risk.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- September 10, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Iterum Therapeutics plc's security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When was the report filed with the SEC?
The report was filed on September 10, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 25 North Wall Quay, Dublin 1, Ireland.
What is the company's telephone number?
The company's telephone number is +353 1 6694820.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 934 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2025-09-10 16:15:28
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
- $1,800,000 — rized share capital of the Company from $1,800,000 to $2,600,000 by the creation of an add
- $2,600,000 b — pital of the Company from $1,800,000 to $2,600,000 by the creation of an additional 80,000,0
Filing Documents
- itrm-20250910.htm (8-K) — 83KB
- 0000950170-25-113986.txt ( ) — 186KB
- itrm-20250910.xsd (EX-101.SCH) — 24KB
- itrm-20250910_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 10, 2025, Iterum Therapeutics plc ( the " Company ") held its 2025 annual general meeting (the " AGM "), at which the Company's shareholders voted on the following proposals, each of which is described in the Company's definitive proxy statement (the " Proxy Statement "), filed with the Securities and Exchange Commission on July 28, 2025. Proposal No. 1: Election of Directors. The shareholders elected David Kelly to the Company's board of directors as a Class I director to serve for a three-year term expiring at the Company's 2028 annual general meeting of shareholders. The results of the shareholders' vote for the election of Mr. Kelly were as follows: Nominee For Against Abstain Broker Non-Votes David Kelly 10,795,342 2,848,953 665,812 8,188,446 Proposal No. 2: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm for 2025 and Authorization of the Board of Directors to Approve the Remuneration of the Independent Registered Public Accounting Firm. The shareholders ratified, in a non-binding vote, the appointment of KPMG as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2025 and authorized the Company's board of directors, acting through its audit committee, to set the independent registered public accounting firm's remuneration. The results of the shareholders' vote were as follows: For Against Abstain Broker Non-Votes 17,986,081 3,759,990 752,482 * Proposal No. 3: Advisory vote on the compensation of the Company's Named Executive Officers. The shareholders did not approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The results of the shareholders' vote were as follows: For Against Abstain Broker Non-Votes 5,406,944 8,449,597 453,566 8,188,446 Proposal No.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: September 10, 2025 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer